What is MRD?
Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.
LEARN MORE ABOUT MRD
The clonoSEQ Assay has been implemented at select centers of excellence in Europe.
The clonoSEQ Assay is being utilized for a variety of investigator-sponsored clinical trials in B-cell lymphoid cancers. If you are interested in learning more about use of clonoSEQ in your own trials, contact dxsupport@adaptivebiotech.com.
Watch our lab tour video* for an overview of the clonoSEQ testing process. Follow a sample as it travels through the lab and is translated into a clonoSEQ patient report.
*This video depicts the clonoSEQ testing process in Adaptive’s single-site laboratory in Seattle, Washington, USA. Some details of the testing process at European sites running the clonoSEQ Assay may vary.
clonoSEQ for Investigators
clonoSEQ leverages the power of next-generation DNA sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.
HOW CLONOSEQ WORKSNews and Updates
Adaptive is proud to partner with industry leaders to respond to this global health pandemic
At Adaptive, we are leveraging the immune system’s natural ability to detect and treat disease to develop clinical products. Understanding the immune response to COVID-19 may lead to solutions to accelerate progress against the disease.
May, 2020
Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.
View Press ReleaseApril, 2020
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.
View Press ReleaseThis page is intended for use by healthcare professionals outside of the United States.
The clonoSEQ Assay B-cell Reagent Set is an in vitro diagnostic that identifies and quantifies rearranged B-cell receptor gene sequences in DNA extracted from blood and bone marrow.
It is a manual test that determines measurable/minimal residual disease (MRD) and monitors changes in disease burden during and after treatment in B-cell malignancies. The test is indicated for use by qualified healthcare professionals for clinical decision-making and in conjunction with other clinicopathological features.
The clonoSEQ Assay is being utilized for a variety of investigator-sponsored clinical trials in B-cell lymphoid cancers. If you are interested in learning more about use of clonoSEQ in your own trials, contact dxsupport@adaptivebiotech.com.
Contact Us
Make an inquiry to learn more about our products.